Clinical trials: Dendritic Cell
Hepatitis C, Chronic, Liver Diseases
Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection
Clearance of HCV infection requires early and multi-specific HLA class I restricted CD8+ T cell and class II restricted CD4+ T cell responses to both structural (Core) and non-structural HCV proteins (NS3, NS4A, NS5A, NS5B).
- Conditions
- Hepatitis C, Chronic, Liver Diseases, Hepatitis, Virus Diseases
- Trial name
- NCT03119025
- Testing
- Autologous DC-vaccines
- Where
- Russia
- Volunteers
- 10 people
- Sponsor
- Russian Academy of Medical Sciences
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines made from a patient's white blood cells mixed with tumor antigens may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00017355
- Testing
- filgrastim, therapeutic autologous dendritic cells
- Where
- United States
- Sponsor
- Baylor Health Care System
Breast Cancer, Triple Negative Breast Cancer
Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells
In this project, the investigators propose the first clinical study in Colombia of vaccination of patients with triple-negative breast cancer (TNBC) using synthetic peptides that contain mutations of the tumor itself that will be…
- Trial name
- NCT04105582
- Testing
- Neo-antigen pulsed Dendritic cell
- Where
- Colombia
- Volunteers
- 5 people
- Sponsor
- Universidad Nacional de Colombia
Sepsis
Dendritic Cells-Derived Exosomes in Human Sepsis
The amount of peripheral blood exosomes has been confirmed to change in the endotoxin-induced infection. The primary objectives of this study are to compare the changes of peripheral blood dendritic cell-derived exosomes in the…
- Trial name
- NCT02957279
- Testing
- Antibiotics
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Jinling Hospital, China
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from a patient's dendritic cells may make the body build an immune response to kill tumor cells. It is not yet known whether combining vaccine therapy with either gp100 antigen or the patient's tumor…
- Trial name
- NCT00085397
- Testing
- autologous dendritic cell-tumor fusion vaccine, gp100 antigen, therapeutic autologous dendritic cells
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
This phase I trial studies the side effects and best dose of rivogenlecleucel, and how well it works, in treating patients with blood cancer that has come back (recurrent) after stem cell transplant.
- Conditions
- Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloproliferative Neoplasm
- Trial name
- NCT03807063
- Testing
- Rivogenlecleucel, Rimiducid
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma
RATIONALE: Biological therapies, such as interferon-gamma and aldesleukin, may stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00616720
- Testing
- aldesleukin, idiotype-pulsed autologous dendritic cell vaccine APC8020, recombinant interferon gamma
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Colorectal Neoplasms, Hepatocellular Carcinoma
Dendritic Killer Cell-based Immunotherapy for Solid Tumors
The primary objective of this study is to evaluate the safety of autologous dendritic killer cell (DKC) in patients with metastatic solid tumor and to evaluate the maximum tolerated dose (MTD) of DKC.
- Conditions
- Colorectal Neoplasms, Hepatocellular Carcinoma, Neoplasm Metastasis
- Trial name
- NCT02882659
- Testing
- Dendritic Killer Cell (DKC)
- Volunteers
- 18 people
- Sponsor
- FullHope Biomedical Co., Ltd.
Ovarian Cancer
Ovarian Dendritic Cell Vaccine Trial
The purpose of this study is to determine if a dendritic cell vaccine made with autologous tumor lysate or for patients who are HLA-A2 with peptides of MUC1 and WT1 therapy will produce remissions in patients with advanced…
- Trial name
- NCT00703105
- Testing
- DC vaccination
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Loyola University
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Umbilical cord blood transplantation may be able to replace cells destroyed by chemotherapy.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00054236
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Case Comprehensive Cancer Center
Non-small Cell Lung Cancer (NSCLC)
A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
Feasibility and Safety study of autologous dendritic cell immunotherapy (AGS-003-LNG) in patients with resectable non-small cell lung cancer.
- Trial name
- NCT02662634
- Testing
- AGS-003-LNG, Carboplatin, Abraxane
- Where
- United States
- Sponsor
- GU Research Network, LLC
GBM, Glioblastoma Multiforme
Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221
The study is an open-label expanded access study for patients for whom vaccine was manufactured during the Northwest Biotherapeutics' 020221 DCVax-L for GBM screening process, but who subsequently failed to meet specific…
- Trial name
- DCVax-L EAP (NCT02146066)
- Testing
- DCVax-L
- Where
- 27 sites in United States
- Sponsor
- Northwest Biotherapeutics
Diffuse Large B Cell Lymphoma, Large B-cell Lymphoma
Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
According to health authorities guidances (FDA 2006, EMA(European Medicines Agency) 2009) for gene therapy clinical trials, observing subjects for delayed adverse events for 15 years is recommended.
- Conditions
- Diffuse Large B Cell Lymphoma, Large B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma Grade 3A
- Trial name
- NCT05377307
- Testing
- Pell's lentiviral-based gene-edited immune cell therapy
- Where
- 5 sites in Taiwan
- Volunteers
- 49 people
- Sponsor
- Pell Bio-Med Technology Co., Ltd.
Prostate Cancer
Vaccine Therapy in Treating Patients With Non-Metastatic Prostate Cancer
RATIONALE: Vaccines made from tumor cells or dendritic cells may help the body build an effective immune response to kill tumor cells. It is not yet known which vaccine is more effective in treating patients with prostate cancer.
- Trial name
- NCT00814892
- Testing
- allogeneic tumor cell vaccine, therapeutic autologous dendritic cells
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Normal Full-Term Deliveries
Generation of Dendritic Cell Precursors From Cord Blood Stem Cells
There is a growing interest in generating dendritic cells (DCs) for using as vaccines. Several cytokines, especially stem cell factor (SCF) and FLT3-ligand (FL), have been identified as essential to produce large numbers of…
- Trial name
- NCT00731744
- Testing
- Normal full-term deliveries
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Glioblastoma
Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Recurrence Of Glioblastoma Multiforme
Rationale of the Study: Treatment for GBM currently consists of surgical resection of the tumour mass followed by radio- and chemotherapy.
- Trial name
- Dendr2 (NCT04002804)
- Testing
- Dendritic Cells Vaccine
- Volunteers
- 26 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
B-cell Non Hodgkin Lymphoma (NHL), DLBCL - Diffuse Large B Cell Lymphoma
A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
This study is a single arm, open label, dose exploring clinical study to evaluate the safety, efficacy, metabolic kinetics and pharmacodynamics of CT1182 cells in patients with relapsed / refractory B-cell non Hodgkin lymphoma…
- Conditions
- B-cell Non Hodgkin Lymphoma (NHL), DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma (FL)
- Trial name
- NCT07548697
- Testing
- CT1182 injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Multiple Sclerosis
Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting Cells
MicroRNAs regulate gene expression. The abnormal expression of microRNAs has been reported in many human diseases. The purpose of this pilot study is to determine if microRNA expression is changed in untreated and…
- Trial name
- NCT01587690
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Prostate Cancer
Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer
The purpose of this study is to determine if the intra-tumoral injection of a subject's own dendritic cells after cryotherapy of the prostate is a safe and effective treatment for advanced prostate cancer.
- Trial name
- CRITICAL (NCT00753220)
- Testing
- VDC2008, Cyclophosphamide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Bostwick Laboratories
Multiple Myeloma, Large-cell Lymphoma
Telehealth-based Symptom Management for Veterans Treated With Selinexor
The purpose of this study is to find out if continued monitoring of side effects from Selinexor and prescribed medication to prevent side effects helps improve symptoms, quality of life, and ability to continue the treatment…
- Trial name
- Selinexor (NCT06452446)
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Durham VA Medical Center